Doseloop Beta

Ranolazine

medication Under review

A prescription anti-anginal medication used to treat chronic stable angina.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

Clinical trials demonstrate ranolazine improves exercise duration, delays angina onset, and reduces angina episodes in patients with chronic stable angina when used as monotherapy or add-on therapy. Evidence from randomized controlled trials supports its efficacy in enhancing functional capacity, though studies primarily involve patients with symptomatic angina rather than completely healthy individuals. Long-term safety data indicate good tolerability with low discontinuation rates due to adverse events.

Reported Benefits

No side effects tracked yet

No side effects have been reported by studies or users for this habit yet.

Research (5 studies)

Meta-Analysis

The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.

StatPearls - NCBI Bookshelf • 2023 • n=12995

Not specified

RCT

Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.

British Journal of Cardiology • 2011 • n=565

Thadani U, et al.

RCT

MERLIN-TIMI 36 Trial: Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes

Journal of the American Medical Association • 2007 • n=6560

Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.

RCT

Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.

Journal of the American Medical Association • 2004 • n=823

Chaitman BR, Skettino SL, Parker JO, et al.

RCT

Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) Trial

Journal of the American Medical Association • 2004 • n=191

Chaitman BR, Pepine CJ, Parker JO, et al.

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 5
Researched benefits 3
Side effects noted 0